InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.060 -0.05 (-45.45%)+
Announcement
Release
25 Feb 2026 7:00PM
Price at Release
$0.110
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Ltd reported its financial results for the half-year ending 31 December 2025. The company recorded a total comprehensive loss of $1,699,413, reflecting substantial expenses related to research and development activities, as well as corporate overheads. Revenue from interest income and R&D tax incentives were $118,396 and $317,905 respectively. The report highlighted a significant increase in losses compared to the previous year, which was $367,554. The company maintained a net working capital surplus and continues to emphasize its R&D efforts in biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. There were no significant changes in the company's state of affairs during the reporting period, and it remains a going concern based on the Directors' assessments. The company's shares are listed on the Australian Securities Exchange under the code NSB.
Key Points
  • Reported total comprehensive loss of $1,699,413 for the half-year ending 31 December 2025.
  • Revenue from interest income amounted to $118,396 and R&D tax incentives to $317,905.
  • Loss for the period increased significantly compared to the previous year's $367,554.
  • Maintained a net working capital surplus with cash and term deposit balances of $6,357,373.
  • Focused on R&D of biomedical products for neurodegenerative and immune-mediated diseases.
  • Directors consider the company a going concern based on financial assessments.
  • No significant changes in the state of affairs during the half-year.
  • Shares listed on the Australian Securities Exchange under code NSB.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.